National Research Council: Committee on a Framework for Developing a New Taxonomy of Disease. Toward precision medicine: Building a knowledge network for biomedical research and a new taxonomy of disease [R]. Washington D C: National Academies Press, 2011.
[2]
Collins F S, Varmus H. A new initiative on precision medicine[J]. New England Journal of Medicine, 2015, 372(9): 793-795.
[3]
Reardon S. Precision-medicine plan raises hopes[J]. Nature, 2015, 517 (7536): 540.
[4]
Lander E S, Linton L M, Birren B, et al. Initial sequencing and analysis of the human genome[J]. Nature, 2001, 409(6822): 860-921.
[5]
Mao J H, Wu D, Perez-Losada J, et al. Crosstalk between Aurora-A and p53: Frequent deletion or downregulation of Aurora- A in tumors from p53 null mice[J]. Cancer Cell, 2007, 11(2): 161-173.
[6]
Mao J H, Perez-Losada J, Wu D, et al. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene[J]. Nature, 2004, 432(7018): 775-779.
[7]
Mao J H, Wu D, Kim I J, et al. Hipk2 cooperates with p53 to suppress γ- ray radiation-induced mouse thymiclymphoma[J]. Oncogene, 2012, 31(9): 1176-1180.
[8]
Mao J H, Wu D, Perez-Losada J, et al. Genetic interactions between Pten and p53 in radiation- induced lymphoma development[J]. Oncogene, 2003, 22(52): 8379-8385.
[9]
Lovly C M, McDonald N T, Chen H, et al. Rationale for co-targeting IGF- 1R and ALK in ALKfusion- positive lung cancer[J]. Nature Medicine, 2014, 20(9): 1027-1034.
[10]
U.S. Department of Health and Human Services, U.S. Food and Drug Administration. Paving the way for personalized medicine: FDA's role in a new era of medical product development[R]. 2013 Oct.
[11]
Venter J C, Adams M D, Myers E W, et al. The sequence of the human genome[J]. Science, 2001, 291(5507): 1304-1351.
[12]
Mao J H, Kim I J, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression[J]. Science, 2008, 321 (5895): 1499-1502.
[13]
Villaruz L C, Socinski M A. Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7mutation[J]. Lung Cancer, 2014, 83(2): 300-301.
[14]
Geiss G K, Bumgarner R E, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs[J]. Nature Biotechnology, 2008, 26(3): 317-325.
[15]
Crystal A S, Shaw A T, Sequist L V, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer [J]. Science, 2014, 346(6216): 1480-1486.
[16]
Grivel J C, Margolis L. Use of human tissue explants to study human infectious agents[J]. Nature Protocols, 2009, 4(2): 256-269.
[17]
Couzin-Frankel J. Hope in a mouse[J]. Science, 2014, 346(6205): 28-29.
[18]
Lancaster M A, Knoblich J A. Organogenesis in a dish: Modeling development and disease using ornaoidtechniques[J]. Science, 2014, 345 (6194): 283-292.
[19]
Nelson C M, Vanduijn M M, Inman J L, et al. Tissue geometry determines sites of mammary branching morphogenesis in organotypiccultures[J]. Science, 2006, 314(5797): 298-300.
[20]
Yu M, Bardia A, Aceto N, et al. Cancer therapy- Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility[J]. Science, 2014, 345(6193): 216-220.
[21]
Celli J P, Rizvi I, BlandenA R, et al. An imaging-based platform for high- content, quantitative evaluation of therapeutic response in 3D tumourmodels[J]. Scientific Reports, 2014, 4(3751): 1-10.
